Bruce E. Strober, MD, PhD, FAAD

University of Connecticut Health Center
21 South Road, Suite 200
Farmington, Connecticut, United States

Specialty: Dermatology

Dr. Bruce Strober, Dermatologist

Research Interests: Psoriasis, Atopic Dermatitis, Hidradenitis Suppurativa, Mycosis Fungoides, Alopecia Areata, Psoriatic Arthritis, Allergic Contact Dermatitis, Common Warts, Plantar Warts, Acne Vulgaris, Pemphigus Vulgaris, Genital Warts, Onychomycosis, Tinea Capitis


Click to view Dr. Bruce Strober's Publications

Strober BE, Langley RGB, Menter A, Magid M, Porter B, Fox T, Safi J Jr, Papavassilis C. No Elevated Risk for Depression, Anxiety, or Suicidality with Secukinumab in a Pooled Analysis of Data from 10 Clinical Studies in Moderate-to-Severe Plaque Psoriasis. Br J Dermatol 2017 Oct 9 [Epub ahead of print]. PMID: 28991372 / doi: 10.1111/bjd.16051

Wan MT, Strober BE, Wu JJ, Shin DB, Gelfand JM. How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials. J Am Acad Dermatol 2017 Sep; 77(3): 569-72. PMID: 28807110 / doi: 10.1016/j.jaad.2017.05.032

Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE. Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Treat 2017 Sep; 28(6): 492-9. Epub 2017 Mar 7. PMID: 28266243 / doi: 10.1080/09546634.2017.1294727

Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value Health 2017 Sep; 20(8): 1174-9. Epub 2017 Jun 16. PMID: 28964451 / doi: 10.1016/j.jval.2016.11.020

Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, Goncalves J, Levi E, Callis Duffin K. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. J Drugs Dermatol 2017 Aug 1; 16(8): 801-8. PMID: 28809995

Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients. Br J Dermatol 2017 Jul 28 [Epub ahead of print]. PMID: 28755394 / doi: 10.1111/bjd.15857

Papp KA, Bachelez H, Blauvelt A, Winthrop KL, Romiti R, Ohtsuki M, Acharya N, Braun DK, Mallbris L, Zhao F, Xu W, Walls CD, Strober B. Infections from 7 clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. Br J Dermatol 2017 Jun 10 [Epub ahead of print]. PMID: 28600810 / doi: 10.1111/bjd.15723

Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Narbutt J, Philipp S, Spelman L, Weglowska J, Zhang N, Strober B. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol 2017 Jun; 76(6): 1093-1102. Epub 2017 Mar 11. PMID: 28291552 / doi: 10.1016/j.jaad.2016.12.014

Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol 2017 Apr; 76(4): 655-61. Epub 2017 Jan 10. PMID: 28087133 / doi: 10.1016/j.jaad.2016.11.043

Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, Ferris LK, Paul C, Lebwohl M, Braun DK, Mallbris L, Wilhelm S, Xu W, Ljungburg A, Acharya N, Reich K. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol 2017 Mar; 76(3): 432-40.e17 [Epub 2016 Nov 23]. PMID: 27889292 / doi: 10.1016/jaad.2016.09.026

De Moll EH, Chang MW, Strober B. Psoriasis in adults and children: Kids are not just little people. Clin Dermatol 2016 Nov-Dec; 34(6): 717-23. Epub 2016 Jul 10. PMID: 27968931 / doi: 10.1016/j/clindermatol.2016.07.006

Martin G, Strober BE, Leonardi CL, Gelfand JM, Blauvelt A, Kavanaugh A, Stein Gold L, Berman B, Rosen T, Stockfleth E. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. J Clin Aesthet Dermatol 2016 Sep; 9(9 Suppl 1): S5-29. Epub Sep 1. PMID: 27800119

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept. J Psoriasis Psoriatic Arthritis 2016 Fall; 1(4): 167-75.

Wu JJ, Strober BE, Hansen PR, Ahlehoff O, Egeberg A, Qureshi AA, Robertson D, Valdez H, Tan H, Wolk R. Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. J Am Acad Dermatol 2016 Nov; 75(5): 897-905. Epub 2016 Aug 4. PMID: 27498960 / doi: 10.1016/j.jaad.2016.06.012

Jinna S, Strober B. Anti-interleukin-17 treatment of psoriasis. J Dermatolog Treat 2016 Aug; 27(4): 311-5. Epub 2016 Mar 4. PMID: 26943806 / doi: 10.3109/09546634.2015.1115816

Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, Gordon KB, Milmont CE, Viswanathan HN, Li J, Pinto L, Harrison DJ, Kricorian G, Nirula A, Klekotka O. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 2016 Jul; 75(1): 77-82.e7. Epub 2016 May 17. PMID: 27206759 / doi: 10.1016/j.jaad.2016.03.026

Strober BE. Why biologic therapies sometimes lose efficacy. Semin Cutan Med Surg 2016 Jun; 35 (4 Suppl 4): S78-80. PMID: 27525443 / doi: 10.12788/j.sder.2016.022

Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, Goyal K, Fakharzadeh S, Calabro S, Langholff W, You Y, Galindo C, Lee S, Lebwohl MG. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol 2016 May; 74(5): 851-861.e4. Epub 2016 Feb 4. PMID: 26853180 / doi: 10.1016/j.jaad.2015.12.017

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol 2016 Apr; 55(4): 401-7. Epub 2016 Feb 11. PMID: 26866518 / doi: 10.1111/ijd.13236

Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nyirady J, Papavassils C, Nelson LM, McLeod LD, Mordin M, Gottlieb AB, Elewski BE, Lebwohl M. Psychometric validation of the psoriasis symptom diary using phase III study data from patients with chronic plaque psoriasis. Int J Dermatol 2016 Mar; 55(3): e147-55. Epub 2015 Oct 30. PMID: 26518255 / doi: 10.1111/ijd.13117

Klufas DM, Wald JM, Strober BE. Treatment of moderate to severe pediatric psoriasis: a retrospective case series. Pediatr Dermatol 2016 Mar; 33(2): 142-9. Epub 2016 Feb 12. PMID: 26871417 / doi: 10.1111/pde.12782

Strober BE, Griffiths CE, O'Dell SJ, Tebbey PW, Barker JN; International Psoriasis Council. Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise. Br J Dermatol 2016 Jan; 174(1): 212-5. Epub 2015 Jun 26. PMID: 26114971 / doi: 10.1111/bjd.13980

Strober B. Interleukin-23 inhibition for the treatment of psoriasis: the next frontier for high-efficacy biologic therapy. Br J Dermatol 201 Oct; 173(4): 887-8. PMID: 26511822 / doi: 10.1111/bjd.14095

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A. Phase 3 Studies Comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015 Oct; 373(14): 1318-28. PMID: 26422722 / doi: 10.1056/NEJMoa1503824

Desai SR, Frieden IJ, Gelfand JM, High W, Kavanaugh A, Marghoob AA, Ozog DM, Rosen T, Stein Gold L, Strober B, Swanson N, Martin G. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting. J Clin Aesthet Dermatol 2015 Sep; 8(9 Suppl): S4-S26. PMID: 26504503

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015 Aug 8; 386(9993): 541-51. Epub 2015 Jun 10. PMID: 26072109 / doi: 10.1016/S0140-6736(15)60125-8

Wald JM, Klufas DM, Strober BE. The use of methotrexate, alone or in combination with other therapies, for the treatment of palmoplantar psoriasis. J Drugs Dermatol 2015 Aug 1; 14(8): 888-92. PMID: 26267735

Papp K, Menter A, Strober B, Kricorian G, Thompson EH, Milmont CE, Nirula A, Klekotka P. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2015 Mar; 72(3): 436-439.e1. Epub 2014 Dec 29. PMID: 25553889 / doi: 10.1016/j.jaad.2014.10.026

Kelly JB 3rd, Foley P, Strober BE. Current and future oral systemic therapies for psoriasis. Dermatol Clin 2015 Jan; 33(1): 91-109. PMID: 25412786 / doi: 10.1016/j.det.2014.09.008

Shlyankevich J, Mehta NN, Krueger JG, Strober B, Gudjonsson JE, Qureshi AA, Tebbey PW, Kimball AB. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related co-morbidities. Am J Med 2014 Dec; 127(12): 1148-1153. Epub 2014 Aug 19. PMID: 25149424 / doi: 10.1016/j.amjmed.2014.08.008

Strober BE, Poulin Y, Teller C, Wang Y, Williams DA, Goldblum OM. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy. J Eur Acad Dermatol Venereol 2014 Dec; 28(12): 1701-6. Epub 2014 Jan 15. PMID: 24422992 / doi: 10.1111/jdv.12372

Casadevall N, Felix T, Strober BE, Warnock DG. Similar names for similar biologics. BioDrugs 2014 Oct; 28(5): 439-44. PMID: 25001080 / doi: 10.1007/s40259-014-0099-9

Chiaravalloti AJ, Strober BE. The use of self-administered subcutaneous methotrexate for the treatment of psoriasis. J Drugs Dermatol 2014 Aug; 13(8): 929-31. PMID: 25116970

Strober BE. Practice gaps. Methotrexate-induced liver toxicity: replacing the liver biopsy. JAMA Dermatol 2014 Aug; 150(8): 862-3. PMID: 24965863 / doi: 10.1001/jamadermatol.2014.681

Bhatia N, Blauvelt A, Brown M, High W, Leonardi CT, Rosen T, Stein Gold L, Stockfleth E, Strober B, Swanson NA, Martin G. Updates on psoriasis and cutaneous oncology: proceedings from the 2014 MauiDerm meeting. J Clin Aesthet Dermatol 2014 Jul; 7(7 Suppl SC2S5-S22): S5-S22. PMID: 25337303

Kimball AB, Leonardi C, Stahle M, Gulliver W, Chevrier M, Fakharzadeh S, Goyal K, Calabro S, Langholff W, Menter A; PSOLAR Steering Committee. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014 Jul; 171(1): 137-47. Epub 2014 Jul 16. PMID: 24684204 / doi: 10.1111/bjd.13013

Lebwohl M. Swensen AR, Nyirady J, Kim E, Gwaltney CJ, Strober BE. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol 2014 Jun; 53(6): 714-22. Epub 2013 Apr 4. PMID: 23557000 / doi: 10.1111/j.1365-4632.2012.05798.x

Kerdel FA, Strober BE. Tumor necrosis factor inhibitors in psoriasis: an update. Semin Cutan Med Surg 2014 Mar; 33(2 Suppl 2): S31-6. PMID: 24979543 / doi: 10.12788/j.sder.0066

Strober BE. Methotrexate and cyclosporine in psoriasis revisited. Semin Cutan Med Surg 2014 Mar; 33(2 Suppl 2): S27-30. PMID: 24979542 / doi: 10.12788/j.sder.0066

Gordon KB, Strober BE. Understanding therapeutic pathways and comorbidities in psoriasis. Semin Cutan Med Surg 2014 Mar; 33(2 Suppl 2): S20-3. PMID: 24979540 / doi: 10.12788/j.sder.0066

Alekseyenko AV, Perez-Perez GI, De Souza A, Strober B, Gao Z, Bihan M, Li K, Methé BA, Blaser MJ. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome 2013 Dec 23; 1(1): 31. PMID: 24451201 / doi: 10.1186/2049-2618-1-31

Strober B. Biologic therapy for psoriasis: early response implies future success. Br J Dermatol 2013 Dec; 169(6): 1178-9. PMID: 24299528 / doi: 10.1111/bjd.12726

Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, Valdez H, Langley RG, Harness J, Menter A, Papp K. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 2013 Nov; 169(5): 992-9. Epub 2013 Jul 16. PMID: 23855761/ doi: 10.1111/bjd.12517

Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 2013 Oct; 27(10): 1252-61. Epub 2012 Nov 16. PMID: 23157612 / doi: 10.1111/j.1468-3083.2012.04705.x

Strober BE, Nyirady J, Mallya UG, Guettner A, Papavassilis C, Gottlieb AB, Elewski BE, Turner-Bowker DM, Shields AL, Gwaltney CJ, Lebwohl M. Item-level psychometric properties for a new patient-reported psoriasis symptom diary. Value Health 2013 Sep-Oct; 16(6): 1014-22. PMID: 24041351 / doi: 10.1016/j.jval.2013.07.002

Blauvelt A, Brown M, Gordon KB, Kavanaugh A, Leonardi CT, Stockfleth E, Strober B, Swanson NA, Martin G. Updates on psoriasis and cutaneous oncology: Proceedings from the 2013 MauiDerm Meeting. J Clin Aesthet Dermatol 2013 Sep; 6(9 Suppl): S2-S20. PMID: 24167640

Babalola O, Strober BE. Treatment of atopic dermatitis in pregnancy. Dermatol Ther 2013 Jul-Aug; 26(4): 293-301. PMID: 23914886 / doi: 10.1111/dth.12074

Babalola O, Strober BE. Management of psoriasis in pregnancy. Dermatol Ther 2013 Jul-Aug; 26(4): 285-92. PMID: 23914885 / doi: 10.1111/dth.12073

Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, Warnock DG. Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther 2013 Jul; 13(7): 1039-47. Epub 2013 Mar 26. PMID: 23527621 / doi: 10.1517/14712598.2013.783560

Tan H, Gupta P, Harness J, Wolk R, Chapel S, Menter A, Strober B, Langley RG, Krishnaswami S, Papp KA. Dose response and pharmacokinetics of tofacitinib (CP-690,550), an oral janus kinase inhibitor, in the treatment of chronic plaque psoriasis. CPT: Pharmacomet Syst Pharmacol 2013 May; 2: e44. doi:10.1038/psp.2013.22

Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K; The PHOENIX 1, PHOENIX 2, ACCEPT Investigators. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from five years of follow-up. Br J Dermatol 2013 Apr; 168(4): 844-854. PMID: 23301632 / doi: 10.1111/bjd.12214

Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH. Topical chemotherapy in cutaneous t-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 2013 Jan 1; 149(1): 25-32. PMID: 23069814 / doi: 10.1001/2013.jamadermatol.541

De Souza A, Ali-Shaw T, Reddy SM, Fiorentino D, Strober BE. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. Br J Dermatol 2013 Jan; 168(1): 210-2. PMID: 23278559 / doi: 10.1111/j.1365-2133.2012.11206.x

Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi consensus approach to challenging case scenarios in moderate-to-severe psoriasis: part 2. Dermatol Ther (Heidelb) 2012 Dec; 2(1): 2. Epub 2012 Mar 30. PMID: 23205325

Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi consensus approach to challenging case scenarios in moderate-to-severe psoriasis: part 1. Dermatol Ther (Heidelb) 2012 Dec; 2(1): 1. Epub 2012 Mar 17. PMID: 23205324

Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM. Sleep quality and other patient-reported outcomes improve after psoriasis patients with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. Br J Dermatol 2012 Dec; 167(6): 1374-81. Epub 2012 Nov 2. PMID: 22897348 / doi: 10.1111/bjd.12000

De Souza A, Strober BE, Merola JF, Oliver S, Franks AG. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol 2012 Oct 1; 11(10): 1224-6. PMID: 23134988

Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M, on behalf of the PSOLAR investigators and Steering Committee. PSOLAR: Design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 2012 Oct; 11(10): 1210-17. PMID: 23134986

Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012 Sep; 167(3): 668-77. PMID: 22924949 / doi: 10.1111/j.1365-2133.2012.11168.x

Santoro FA, Rothe MJ, Strober BE. Ethical considerations when prescribing biologics in dermatology. Clin Dermatol 2012 Sep; 30(5): 492-5. PMID: 22902219

Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K, Thompson EH, Hooper M, Kricorian G. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 2012 Sep; 167(3): 649-57. PMID: 22533447 / doi: 10.1111/j.1365-2133.2012.11015.x

Marmon S, De Souza A, Strober BE. Letter: Psoriasis and Down syndrome: a report of three cases and a potential pathophysiologic link. Dermatol Online J 2012 Jun; 18(6): 13. PMID: 22747937

Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, Guzzo C, Li S, Hsu MC, Strober B. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials. J Am Acad Dermatol 2012 May; 66(5): 731-41. Epub 2011 Sep 17. PMID: 21930328 / doi:10.1016/j.jaad.2011.06.011

Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012 Feb; 132(2): 304-14. Epub 2011 Oct 20. PMID: 22011907 / doi: 10.1038/jid.2011.304

Strober BE, Armour K, Romiti R, Smith C, Tebbey PW, Menter A, Leonardi C. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol 2012 Feb; 66: 317-22. PMID: 22243723 / doi:10.1016/j.jaad.2011.08.034

Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012 Jan; 148(1): 95-102. PMID: 22250239 / doi: 10.1001/archdermatol.2011.1410

Leonardi C, Papp K, Strober B, Reich K, Asahina A, Gu Y, Beason J, Rozzo S, Tyring S. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol 2011 Oct 1; 12(5): 321-37. PMID: 21834597 / doi: 10.2165/11587890-000000000-00000

Lynde C, Krell J, Korman N, Mathes B; Vaccine Study Investigators. Immune response to pneumococcal polysaccharide vaccine in adults with chronic plaque psoriasis treated with alefacept. J Am Acad Dermatol 2011 Oct; 65(4): 799-806. Epub 2011 Mar 30. PMID: 21453987 / doi: 10.1016/j.jaad.2010.04.040

Strober BE, Crowley JJ, Yamauchi P, Olds M, Williams DA. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients moderate to severe chronic plaque psoriasis. Br J Dermatol 2011 Sep; 165(3): 661-8. Epub 2011 Jul 28. PMID: 21574984 / doi: 10.1111/j.1365-2133.2011.10419.x

Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A. The association between biological therapies for chronic plaque psoriasis and cardiovascular events; a meta-analysis of randomized controlled trials. JAMA 2011 Aug, 24; 306: 864-71. PMID: 21862748 / doi:10.1001/jama.2011.1211

De Souza A, Ali-Shaw T, Strober BE, Franks AG Jr. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol 2011 Aug; 147(8): 896-8. PMID: 21844448 / doi:10.1001/archdermatol.2011.185

Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, Smith C; International Psoriasis Council. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol 2011 Jul; 25(7): 758-64. Epub 2010 Dec 29. PMID: 21198946 / doi: 10.1111/j.1468-3083.2010.03932.x

Strober BE, Poulin Y, Kerdel FA, Langley RG, Gu Y, Gupta SR, Okun MM, Papp KA. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Amer Acad Dermatol 2011 Apr; 64(4): 671-681. PMID: 21414495 / doi:10.1016/j.jaad.2010.03.009

Bangert C, Strober BE, Cork M, Ortonne JP, Luger T, Bieber T, Ferguson A, Ecker RC, Kopp T, Weise-Riccardi S, Guettner A, Stingl G. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial. Dermatology 2011 Feb; 222(1): 36-48. Epub 2010 Dec 8. PMID: 21150167 / doi:10.1159/000321711

De Souza A, Solomon GE, Strober BE. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull NYU Hosp Jt Dis 2011; 69: 185-7. PMID: 220355400

Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: consensus conference. J Amer Acad Dermatol 2011; 64(6): 1179. PMID: 21571176 / doi:10.1016/j.jaad.2011.10.034

Brauer JA, Mandal R, Walters R, Solomon G, Kundu RV, Strober BE. Disseminated superficial porokeratosis. Dermatol Online J 2010 Nov 15; 16(11) :20. PMID: 21163171

Leonardi C, Strober B, Gottlieb AB, Elewski BE, Ortonne JP, van de Kerkhof P, Chiou CF, Dunn M, Jahreis A. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol 2010 Aug; 9(8): 928-37. PMID: 20684143

Langley RG, Strober BE, Gu Y, Rozzo SJ, Okun MM. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010 Jun; 162(6): 1349-58. Epub 2010 Apr 14. PMID: 20394634 / doi: 10.1111/j.1365-2133.2010.09707.x

Levine D, Strober BE. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Semin Cutan Med & Surg 2010 Mar; 29(1): 28-34. PMID: 20430305

Menon K, Van Voorhees AS, Bebo BF Jr., Gladman DD, Hsu S, Kalb RE, Lebwohl MG, Strober BE. National Psoriasis Foundation. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Amer Acad Dermatol 2010 Feb; 62(2): 291-9. Epub 2009 Jul 31. PMID: 19646777 / doi:10.1016/j.jaad.2009.03.047

Griffiths CEM, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley L, Goldstein N, Menter A, for the ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362(2): 118-28. PMID: 20071701 / doi:10.1056/NEJMoa0810652.

Strober BE, Menon K, McMichael A, Hordinsky M., Krueger G, Panko J, Siu K, Lustgarten J, Ross E, Shapiro J. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. Arch Dermatol 2009 Nov; 145(11): 1262-1266. PMID: 19917955 / doi:10.1001/archdermatol.2009.264

Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Amer Acad Dermatol 2009 May; 60(5): 824-37. PMID: 19389524 / doi:10.1016/j.jaad.2008.11.906

Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Amer Acad Dermatol 2009; 61(1 Suppl 1): S1-S46. PMID: 19527820 / doi:10.1016/j.jaad.2009.03.017

Marmon S, Strober BE. Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumab. J Invest Dermatol 2008 Nov; 128(11): 2567-9. PMID: 18927537 / doi:10.1038/jid.2008.291

Victor F, Menon K, Latkowski JA, Fernandez-Obregon A, Strober BE. Efalizumab-associated Guillain-Barre syndrome. Arch Dermatol 2008 Oct; 144(10): 1396-7. PMID: 18936412 / doi:10.1001/archderm.144.10.1396

Gao Z, Tseng C-H, Strober BE, Pei Z, Blaser MJ. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS ONE 2008 Jul 23; 3(7): e2719. PMID: 18648509 / doi:10.1371/journal.pone.0002719

Kazanis M, Leonardi C, Gordon K, Strober B, Menter A, Kimball AB. Rethinking eligibility creep. J Amer Acad Dermatol 2008 Jul; 59(1): 165-7. PMID: 18571602 / doi:10.1016/j.jaad.2008.02.041

Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG; for the National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008 Jun; 58(6): 1031-42. Epub 2008 Mar 4. PMID: 18313171 / doi: doi:10.1016/j.jaad.2008.01.006

Strober BE, Teller C, Yamauchi P, Miller JL, Hooper M, Yang, Y-C, Dann F. Effects of etanercept on C-Reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008 Aug; 159(2): 322-30. Epub 2008 May 22. PMID: 18503600 / doi:10.1111/j.1365-2133.2008.08628.x

Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008 May; 24(5): 1529-38. Epub 2008 Apr 16. PMID: 18419879 / doi:10.1185/030079908X301866

Levy MS, Polsky D, Davidson A, Strober BE. Tinea versicolor associated with etanercept therapy. J Am Acad Dermatol. 2008 May; 58(5 Suppl 1): S99-100. PMID: 18489062

Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008 Jan; 58(1): 94-105. Epub 2007 Nov 5. PMID: 17980456 / doi:10.1016/j.jaad.2007.08.030

Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008 Jan; 58(1): 106-15. Epub 2007 Oct 23. PMID: 17936411 / doi:10.1016/j.jaad.2007.09.010

Strober BE, Kim C, Siu K. Efalizumab for the treatment of refractory hidradenitis suppurativa. J Am Acad Dermatol 2007 Dec; 57(6): 1090-1. PMID: 18021852 / doi:10.1016/j.jaad.2007.07.032

Sterry W, Strober BE, Menter A. On behalf of the International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007 Oct; 157(4): 649-55. PMID: 17627791

Strober BE, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther 2007 Jul-Aug; 20(4): 270-6. PMID: 17970892

Brownell I, Strober BE. Folate with methotrexate: big benefit, questionable cost. Br J Dermatol 2007 Jul; 157(1): 213. PMID: 17578449 / doi:10.1111/j.1365-2133.2007.08005.x

Henning JS, Gruson LM, and Strober BE. Reconsidering Liver Biopsies during Methotrexate Therapy. J Am Acad Dermatol 2007 May; 56(5): 893-4. PMID: 17437899 / doi:10.1016/j.jaad.2006.12.005

Frankel EH, Strober BE, Crowley JJ, Fivenson DP, Woolley JM, Yu EB, Xia HA, Chiou CF, Stevens SR. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis 2007 Apr; 79(4): 322-6. PMID: 17500381

Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ, for the National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007 Feb; 143(2): 239-242. PMID: 17310004/ doi:10.1001/archderm.143.2.239

Srivastava M, Solomon G, Strober B. Psoriatic onycho-pachydermo periostitis. Dermatol Online J 2007 Jan; 13(1): 20. PMID: # 17511953

Stein JA, Fangman B, Strober B. Actinic granuloma. Dermatol Online J 2007 Jan; 13(1): 19. PMID: 17511952

Flood J, Mihalik C, Fleming RR, Strober BE, Zucker DR, Burgoyne DS. The use of therapeutic interchange for biologic therapies. Managed Care 2007 Jan; 16(1): 51-62. PMID: 1728581

Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol 2007 Jan; 156(1): 138-42. PMID: 17199580 / doi:10.1111/j.1365-2133.2006.07585.x

Leonardi CL, Strober BE. On multiple courses of alefacept. J Am Acad Dermatol 2006 Nov; 55(5): 916-7. PMID: 17052512

Paulino LC, Tseng CH, Strober BE, and Blaser MJ. Molecular analysis of fungal microbiota in samples from healthy human skin and psoriatic lesions. Journal Clin Microbiol 2006 Aug; 44(8): 2933-41. PMID: 16891514 / doi:10.1128/JCM.00785-06

Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006 Jul; 33(7): 1442-6. Epub 2006 May 15. PMID: 16724368

Belsito D, Wilson DC, Warshaw E, Fowler J, Ehrlich A, Anderson B, Strober BE, Willetts JA. Prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol 2006 Jul; 55(1): 40-6. Epub 2006 May 26. PMID: 16781290 / doi:10.1016/j.jaad.2006.03.025

Leyden J, Thiboutot DM, Shalita AR, Webster G, Washenik K, Strober BE, Shupack J. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol 2006 May; 142(5): 605-12. PMID: 16702498 / doi:10.1001/archderm.142.5.605

Gottlieb AB, Kircik L, Eisen D, Jackson JM, Boh EE, Strober BE, Frankel E, Xia HA, Stevens SR. Use of etanercept for psoriatic arthritis in the dermatology clinic: the experience diagnosing, understanding care, and treatment with etanercept (EDUCATE) study. J Dermatol Treat 2006; 17(6): 343-52. PMID: 17853307 / doi:10.1080/09546630600967166

Strober BE. Successful treatment of plaque psoriasis with self-administered, subcutaneous alefacept. Arch Dermatol, 2005 Dec; 141(12): 1602. PMID: 16365271 / doi:10.1001/archderm.141.12.1602-a

Alexis A and Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg 2005 Dec; 9(6): 296-302. PMID: 16699906

Strober BE, Menon K. Folate Supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol 2005 Oct; 53(4): 652-9. PMID: 16198787 / doi:10.1016/j.jaad.2005.06.036

Strober BE, Siu K, Alexis A, Kim G, Washenik K, Sinha A, Shupack J. Etanercept does not effectively treat moderate to severe alopecia areata: an open label study. J Am Acad Dermatol 2005 Jun; 52(6): 1082-4. PMID: 15928633 / doi:10.1016/j.jaad.2005.03.039

Cassetty C, Alexis AF, Shupack JL, Strober BE. Alefacept in the treatment of psoriatic nail disease: a small case series. J Am Acad Dermatol 2005 Jun; 52(6): 1101-2. PMID: 15928640 / doi:10.1016/j.jaad.2005.01.101

Rosmarin D and Strober BE. The potential of interleukin-12 inhibition in the treatment of psoriasis. J Drugs Dermatol 2005 May-Jun; 4(3): 318-25. PMID: 15898287

Rosenberg BE and Strober BE. Acrodermatitis continua. Dermatol Online J. 2004 Nov; 10(3): 9. PMID: 15748579

Strober BE, Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities. J Drugs Dermatol 2004 May-Jun; 3(3): 270-2. PMID: 15176161

Arroyo MP, Sanders S, Yee H, Schwartz D, Kamino H, Strober BE. Toxic epidermal necrolysis-like reaction secondary to colchicine overdose. Br J Dermatol 2004 Mar; 150(3): 581-88. PMID: 15030347 / doi:10.1111/j.1365-2133.2004.05838.x

Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Arch Dermatol 2004 Mar; 140(3): 366. PMID:15023789 / doi:10.1001/archderm.140.3.366

Saini R, Tutrone W, and Strober BE. The Kobner phenomenon and psoriatic arthritis. Cutis 2003 Nov; 72(5): 405-6. PMID: 14655783

Strober BE. Generalized morphea. Dermatol Online J 2003 Oct; 9(4): 24. PMID: 14594597

Strober BE. Pachyonychia congenita, type II. Dermatol Online J 2003 Oct; 9(4): 12. PMID: 14594585

Strober BE. Erythrokeratodermia variabilis. Dermatol Online J 2003 Oct; 9(4): 5. PMID: 14594578

Strober BE. Lupus panniculitis (lupus profundus). Dermatol Online J 2001 Dec; 7(2): 20. PMID: 12165236

Gallagher TC, Strober BE. Cutaneous Bacillus anthracis infection. N Engl J Med 2001 Nov 29; 345(22): 1646-7. Epub 2001 Nov 8. PMID: 11704683

Strober BE. Tinea capitis. Dermatol Online J 2001 Feb; 7(1): 12. PMID: 11328633

Strober BE, Potash S, and Grossman ME. Eyelash hypertrichosis in a patient treated with topical latanoprost. Cutis 2001 Feb; 67(2): 109-10. PMID: 11236218

Strober BE, Dunaief JL, Guha S, and Goff SP. Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Mol Cell Biol 1996 Apr; 16(4): 1576-83. PMID: 8657132

Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, Begemann M, Crabtree GR, Goff SP. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 1994 Oct 7; 79(1): 119-30. PMID: 7923370 / doi:10.1016/0092-8674(94)90405-7

Avigan MI, Strober B, Levens D. A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. Journal of Biological Chemistry 1990 Oct 25; 265(30): 18538-45. PMID: 2211718

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.